年龄作为华法林敏感性的一个决定因素。
Age as a determinant of sensitivity to warfarin.
作者信息
Shepherd A M, Hewick D S, Moreland T A, Stevenson I H
出版信息
Br J Clin Pharmacol. 1977 Jun;4(3):315-20. doi: 10.1111/j.1365-2125.1977.tb00719.x.
Abstract
1 Parallel human and rat studies were carried out to confirm the previous suggestion of an increased sensitivity to warfarin in old age. 2 The anticoagulant response to warfarin was found to be greater in the elderly groups despite, in the case of the patient study, the elderly subjects being given a smaller weight-related dose. 3 At the same plasma warfarin concentrations there was greater inhibition of vitamin K-dependent clotting factor synthesis in the elderly. There was no difference in the rate of clotting factor degradation in the two age groups. 4 There was no appreciable difference in warfarin pharmacokinetics (plasma half-life, apparent volume of distribution, plasma clearance, plasma protein binding or plasma warfarin alcohol levels) in the two age groups. 5 There appeared to be no major age-related differences in warfarin pharmacokinetics and the increased effect of warfarin in the elderly seemed to result from an increased intrinsic sensitivity to warfarin.
摘要
- 开展了平行的人体和大鼠研究，以证实先前关于老年人对华法林敏感性增加的推测。2. 结果发现，老年组对华法林的抗凝反应更大，尽管在患者研究中，老年受试者按与体重相关的剂量给予的药物较少。3. 在相同的血浆华法林浓度下，老年人中维生素K依赖的凝血因子合成受到的抑制更大。两个年龄组的凝血因子降解速率没有差异。4. 两个年龄组在华法林药代动力学（血浆半衰期、表观分布容积、血浆清除率、血浆蛋白结合或血浆华法林酒精水平）方面没有明显差异。5. 华法林药代动力学似乎没有与年龄相关的主要差异，华法林在老年人中作用增强似乎是由于对华法林的内在敏感性增加所致。
相似文献
1
Age as a determinant of sensitivity to warfarin.年龄作为华法林敏感性的一个决定因素。
Br J Clin Pharmacol. 1977 Jun;4(3):315-20. doi: 10.1111/j.1365-2125.1977.tb00719.x.
2
Comparative pharmacokinetics of coumarin anticoagulants XXV: Warfarin-ibuprofen interaction in rats.香豆素类抗凝血剂的比较药代动力学XXV：大鼠体内华法林与布洛芬的相互作用。
J Pharm Sci. 1977 Jul;66(7):943-7. doi: 10.1002/jps.2600660710.
3
Warfarin sodium: steady-state plasma levels and patient age.华法林钠：稳态血浆水平与患者年龄
Clin Exp Pharmacol Physiol. 1978 Mar-Apr;5(2):143-9. doi: 10.1111/j.1440-1681.1978.tb00664.x.
4
A Joint Model for Vitamin K-Dependent Clotting Factors and Anticoagulation Proteins.维生素 K 依赖的凝血因子和抗凝蛋白的联合模型。
Clin Pharmacokinet. 2017 Dec;56(12):1555-1566. doi: 10.1007/s40262-017-0541-5.
5
Effect of plasma protein binding on the anticoagulant action of warfarin in rats.血浆蛋白结合对大鼠华法林抗凝作用的影响。
Res Commun Chem Pathol Pharmacol. 1975 Oct;12(2):405-8.
6
Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin.急性病毒性肝炎对华法林处置和药理作用的影响。
Clin Pharmacol Ther. 1976 Jul;20(1):90-7. doi: 10.1002/cpt197620190.
7
Effect of naproxen on the kinetics of elimination and anticoagulant activity of a single dose or warfarin.萘普生对单剂量华法林消除动力学及抗凝活性的影响。
Clin Pharmacol Ther. 1979 Jan;25(1):51-60. doi: 10.1002/cpt197925151.
8
Effect of warfarin on the kinetics of the vitamin K-dependent clotting factors in rats.华法林对大鼠维生素K依赖凝血因子动力学的影响。
J Pharmacol Exp Ther. 1977 May;201(2):507-17.
9
Comparative pharmacokinetics of coumarin anticoagulants XV: relationship between pharmacokinetics of dicumarol and warfarin in rats.香豆素类抗凝剂的比较药代动力学XV：双香豆素与华法林在大鼠体内的药代动力学关系
J Pharm Sci. 1975 Dec;64(12):1995-98. doi: 10.1002/jps.2600641220.
10
Effect of naproxen on the steady-state serum concentration and anticoagulant activity of warfarin.萘普生对华法林稳态血清浓度及抗凝活性的影响。
Clin Pharmacol Ther. 1979 Jan;25(1):61-6. doi: 10.1002/cpt197925161.
引用本文的文献
1
Usefulness of STOPP/START criteria and Beers criteria for prescribing in geriatric patients in a tertiary health care center, Raipur, Central India.印度中部赖布尔一家三级医疗中心采用STOPP/START标准和Beers标准指导老年患者用药的效用
J Family Med Prim Care. 2022 Nov;11(11):7064-7071. doi: 10.4103/jfmpc.jfmpc_733_22. Epub 2022 Dec 16.
2
Unusual case of cerebral embolism after initiation of selexipag for sarcoidosis-related pulmonary hypertension: a case report.使用司来帕格治疗结节病相关肺动脉高压后发生脑栓塞的罕见病例：一例报告
Radiol Case Rep. 2022 Jun 18;17(9):3009-3014. doi: 10.1016/j.radcr.2022.05.064. eCollection 2022 Sep.
3
Age-Related Change in Hepatic Clearance Inferred from Multiple Population Pharmacokinetic Studies: Comparison with Renal Clearance and Their Associations with Organ Weight and Blood Flow.从多项群体药代动力学研究推断的肝脏清除率的年龄相关性变化：与肾脏清除率的比较及其与器官重量和血流量的关联
Clin Pharmacokinet. 2022 Feb;61(2):295-305. doi: 10.1007/s40262-021-01069-z. Epub 2021 Sep 13.
4
Physiologically-Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV.基于生理学的药代动力学模型结合瑞士艾滋病毒队列研究数据支持无需调整老年艾滋病毒感染者中比克替拉韦的剂量。
Clin Pharmacol Ther. 2021 Apr;109(4):1025-1029. doi: 10.1002/cpt.2178. Epub 2021 Feb 27.
5
Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.新型中度环氧化酶-2（COX-2）抑制剂依美昔布对健康志愿者中美华法林药代动力学和药效学的影响。
Sci Rep. 2019 Oct 31;9(1):15774. doi: 10.1038/s41598-019-51755-z.
6
Warfarin dose requirement in patients having severe thrombosis or thrombophilia.严重血栓形成或血栓形成倾向患者的华法林剂量需求。
Br J Clin Pharmacol. 2019 Aug;85(8):1684-1691. doi: 10.1111/bcp.13948. Epub 2019 Jun 17.
7
Bleeding Complications in Warfarin-Treated Patients Admitted to the Emergency Department.华法林治疗患者在急诊科就诊时的出血并发症
J Clin Med Res. 2019 Feb;11(2):106-113. doi: 10.14740/jocmr3669. Epub 2019 Jan 5.
8
Establishment of a Han Chinese-specific pharmacogenetic-guided warfarin dosing algorithm.建立针对汉族人群的药物遗传学指导的华法林给药算法。
Medicine (Baltimore). 2018 Sep;97(36):e12178. doi: 10.1097/MD.0000000000012178.
9
Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients.用于预测印度患者稳定维持剂量的华法林剂量模型
Clin Appl Thromb Hemost. 2018 Mar;24(2):353-359. doi: 10.1177/1076029616683046. Epub 2017 Jan 4.
10
Incidence and Determinants of Traumatic Intracranial Bleeding Among Older Veterans Receiving Warfarin for Atrial Fibrillation.接受华法林抗凝治疗的老年房颤退伍军人创伤性颅内出血的发生率和决定因素。
JAMA Cardiol. 2016 Apr 1;1(1):65-72. doi: 10.1001/jamacardio.2015.0345.
本文引用的文献
1
Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin.人体药理效应动力学：华法林的抗凝作用
Clin Pharmacol Ther. 1969 Jan-Feb;10(1):22-35. doi: 10.1002/cpt196910122.
2
Predisposing factors in adverse reactions to drugs.药物不良反应的诱发因素。
Br Med J. 1969 Mar 1;1(5643):536-9. doi: 10.1136/bmj.1.5643.536.
3
Efficacy and toxicity of heparin in relation to age and sex.
N Engl J Med. 1968 Aug 8;279(6):284-6. doi: 10.1056/NEJM196808082790603.
4
Effect of age and sex on human drug metabolism.年龄和性别对人体药物代谢的影响。
Br Med J. 1971 Sep 11;3(5775):607-9. doi: 10.1136/bmj.3.5775.607.
5
Vocational training for general practice: a preliminary report.全科医学职业培训：初步报告。
Br Med J. 1971 Jan 2;1(5739):41-3. doi: 10.1136/bmj.1.5739.41.
6
The assay of warfarin in plasma or stool.血浆或粪便中华法林的测定。
Biochem Med. 1970 Dec;4(5):376-82. doi: 10.1016/0006-2944(70)90065-7.
7
Rate of aminopyrine disappearance from plasma in young and aged humans.
Pharmacology. 1972;8(4):273-9. doi: 10.1159/000136343.
8
Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man.
J Pharm Pharmacol. 1973 Jun;25(6):458-65. doi: 10.1111/j.2042-7158.1973.tb09133.x.
9
Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding.药物代谢随年龄增长的变化：2. 苯妥英钠清除率与蛋白结合率
Br J Clin Pharmacol. 1975 Feb;2(1):73-9. doi: 10.1111/j.1365-2125.1975.tb00475.x.
10
Changes in drug metabolism with increasing age: 1. warfarin binding and plasma proteins.药物代谢随年龄增长的变化：1. 华法林与血浆蛋白的结合
Br J Clin Pharmacol. 1975 Feb;2(1):69-72. doi: 10.1111/j.1365-2125.1975.tb00474.x.
Zotero 插件